DOCSLIB.ORG

Episodic Visual Snow Associated with Migraine Attacks

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Episodic Visual Snow Associated with Migraine Attacks Letters RESEARCH LETTER Discussion | Three patients report episodes of VS exclusively at the beginning or during migraine attacks. The description was Episodic Visual Snow Associated identical and matched the definition of VS in VSS except for With Migraine Attacks not being continuous.1,2 In the syndrome-defining study,1 only Visual snow syndrome (VSS) is a debilitating disorder charac- patients with continuous VS were included, impeding the iden- terized by continuous visual snow (VS), ie, tiny flickering dots tification of an episodic form. Based on the present case se- in the entire visual field resembling the view of a badly tuned ries, we propose to distinguish between VSS, a debilitating dis- analog television (Figure), plus additional visual symptoms, order characterized by continuous VS and additional visual such as photophobia and palinopsia. There is a high comor- symptoms persisting over years, and eVS, an uncommon self- 1 bidity with migraine and migraine aura. To our knowledge, limiting symptom during migraine attacks. this is the first report of patients with an episodic form of VS The relationship between migraine and VSS is still (eVS), strictly co-occurring with migraine attacks. unresolved.3 Although the severity of VS in VSS does not fluc- tuate in parallel to the migraine cycle,1 the strict co-occurrence Methods | Between January 2016 and December 2017, we saw of eVS and migraine reported here epitomizes a close proxim- 3 patients with eVS and 1934 patients with migraine at our ter- ity.This is in agreement with the clinical picture of migraine being tiary outpatient headache center. Diagnoses were made ac- a disorder of sensory processing4 and VSS being a disorder of vi- cording to the International Headache Society International sual processing1 and also with neuroimaging showing overlap- Classification of Headache Disorders-32 and our previous work,1 ping dysfunctional areas in the visual association cortex.3,5 except for the requirement of permanence for VS. The case se- Episodic VS is uncommon given that only 3 of 1934 patients ries was approved by the Cantonal Ethics Committee Bern (Req- with migraine (<0.2%) were identified despite asking routinely 2017-00698) with waiver of written informed consent based for visual symptoms. It was remarkably linked to migraine attacks on general consent given by all patients. and occurred without the additional symptoms found in VSS.1 In Results | The 3 patients presented initially for headache as chief the first patient, the occurrence prior to headache attacks might complaint. They denied VS outside migraine attacks and did suggest an aura phenomenon. However, the history of migraine not report additional visual symptoms suggestive of VSS dur- without aura in all patients, the brief duration in 1 patient and long ing headache except for photophobia. Neurological examina- duration in 2 patients, the affection of the entire visual field, and tion and magnetic resonance imaging results were normal. the lack of directed movement speak against a cortical spreading 6 Patients experienced black and white (2 patients) or black depressionlike mechanism and thus against eVS being an aura and yellow (1 patient) eVS during migraine attacks, nonfluc- symptom. In clinical practice, a detailed history in patients report- tuating in distribution and severity. Episodes lasted from less ing visual flickering is therefore necessary to differentiate aura than 2 minutes before and during the attack in 1 patient to dur- from eVS. This is important because the diagnosis of aura might ing the entire migraine attack in 2 patients. have implications for patient guidance on contraception or tim- ing of triptan intake. Figure. Visual Snow Resembling the View of a Badly Tuned Julius Hodak, MD Analog Television Urs Fischer, MD Claudio L. A. Bassetti, MD A Normal vision B Visual snow Christoph J. Schankin, MD Author Affiliations: Department of Neurology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland. Corresponding Author: Christoph J. Schankin, MD, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, CH-3010 Bern, Switzerland ([email protected]). Accepted for Publication: September 26, 2019. Published Online: November 25, 2019. doi:10.1001/jamaneurol.2019.4050 Author Contributions: Dr Schankin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Hodak, Schankin. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Hodak, Schankin. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Hodak, Schankin. Obtained funding: Schankin. Administrative, technical, or material support: Hodak. Supervision: Bassetti, Schankin. 392 JAMA Neurology March 2020 Volume 77, Number 3 (Reprinted) jamaneurology.com © 2019 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 Letters Conflict of Interest Disclosures: Dr Fischer reports grants from the Swiss sociated with increased β-amyloid deposition5 indepen- National Science Foundation, Swiss Heart Foundation, and Medtronic and dently of brain vascular burden, suggesting that gait served as a consultant for Stryker, Medtronic, and CSL Behring outside the submitted work. Dr Schankin reports grants from Swiss Heart Foundation performance may reflect brain pathological burden. 1 outside the submitted work; personal fees from Novartis, Eli Lilly and Company, The findings from Jack et al also confirm that the asso- Almirall, and Allergan outside the submitted work; and personal fees and ciation between AD pathology load and cognitive symptoms nonfinancial support from Teva Pharmaceuticals and Amgen outside the lessens with age. The role of noncognitive symptoms can be submitted work. No other disclosures were reported. even more important in elderly individuals, acting as mark- Funding/Support: This work was supported by Deutsche Migräne-und Kopfschmerzgesellschaft, Eye on Vision Foundation, and Baasch-Medicus ers of impeding decline by reflecting the individual’s brain sus- Foundation. ceptibility to brain pathology load. There is a biological plau- Role of the Funder/Sponsor: The funders had no role in the design and sibility about a shared mechanism because accumulating conduct of the study; collection, management, analysis, and interpretation of knowledge indicates that cognitive and motor symptoms are the data; preparation, review, or approval of the manuscript; and decision to not causally interassociated; instead they reflect a burden in submit the manuscript for publication. 1. Schankin CJ, Maniyar FH, Digre KB, Goadsby PJ. ‘Visual snow’: a disorder brain networks shared by cognitive and motor control. distinct from persistent migraine aura. Brain. 2014;137(pt 5):1419-1428. doi:10. We believe that motor and behavioral symptoms should 1093/brain/awu050 be considered along with cognitive symptoms and pathologi- 2. Headache Classification Committee of the International Headache Society cal biomarkers to achieve improved sensitivity and specific- (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. ity for classifying risk, identifying phenotypes, and pre- 3. Schankin CJ, Maniyar FH, Sprenger T, Chou DE, Eller M, Goadsby PJ. The dicting disease progression. In this context, asymptomatic relation between migraine, typical migraine aura and “visual snow”. Headache. individuals might be cognitively asymptomatic but have 2014;54(6):957-966. doi:10.1111/head.12378 motor or behavioral changes reflecting underlying pathol- 4. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, ogy. This would help to better understand the variability of Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. doi:10.1152/physrev.00034.2015 the clinical manifestations of neurodegeneration in aging, 5. Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Géraud G. and importantly, to detect those who may be candidates for Photophobia in migraine: an interictal PET study of cortical hyperexcitability neuroprotective trials aimed at delaying clinical onset of and its modulation by pain. J Neurol Neurosurg Psychiatry. 2010;81(9):978-984. dementia. doi:10.1136/jnnp.2009.190223 6. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad SciUSA. Manuel Montero-Odasso, MD, PhD, FRCPC 2001;98(8):4687-4692. doi:10.1073/pnas.071582498 Zahinoor Ismail, MD, FRCPC Richard Camicioli, MD, FRCPC COMMENT & RESPONSE Author Affiliations: Gait and Brain Lab, Parkwood Institute, Lawson Health Research Institute, School of Medicine and Dentistry, Division of Geriatric Alzheimer Disease, Biomarkers, Medicine, Departments of Medicine and Epidemiology and Biostatistics, and Clinical Symptoms—Quo Vadis? University of Western Ontario, London, Ontario, Canada (Montero-Odasso); To the Editor We read with interest the article from Jack et al,1 University of Calgary, Calgary, Alberta, Canada (Ismail); University of Alberta, and its Editorial that shows that the prevalence of 2 neuro- Edmonton, Alberta, Canada (Camicioli). pathologic hallmarks of Alzheimer disease (AD), β-amyloid Corresponding Author: Manuel M. Montero-Odasso, MD, PhD, FRCPC, Gait and Brain Lab, Parkwood Institute,
Load more

Recommended publications
  • Stand up to Chronic Migraine with Botox®
    #1 PRESCRIBED BRANDED TREATMENT FOR CHRONIC MIGRAINE* Chronic Migraine DON’T LIE DOWN BOTOX ® STAND UP TO Prevention CHRONIC MIGRAINE® WITH BOTOX Treatment Experience Treatment *Truven Health MarketScan Data, October 2010-April 2017. Prevent Headaches and Migraines Before They Even Start BOTOX ® BOTOX® prevents on average 8 to 9 headache days and migraine/probable migraine days a month (vs 6 to 7 for placebo) Savings Program For adults with Chronic Migraine, 15 or more headache days a month, each lasting 4 hours or more. BOTOX® is not approved for adults with migraine who have 14 or fewer headache days a month. Indication • Spread of toxin effects. The effect of botulinum toxin may affect areas BOTOX® is a prescription medicine that is injected to prevent headaches in adults away from the injection site and cause serious symptoms including: loss of with chronic migraine who have 15 or more days each month with headache strength and all-over muscle weakness, double vision, blurred vision and lasting 4 or more hours each day in people 18 years or older. drooping eyelids, hoarseness or change or loss of voice, trouble saying words It is not known whether BOTOX® is safe or effective to prevent headaches clearly, loss of bladder control, trouble breathing, trouble swallowing. in patients with migraine who have 14 or fewer headache days each month There has not been a confirmed serious case of spread of toxin effect away from (episodic migraine). the injection site when BOTOX® has been used at the recommended dose to IMPORTANT SAFETY INFORMATION treat chronic migraine. Resources BOTOX® may cause serious side effects that can be life threatening.
    [Show full text]
  • Clinical Rating Scale for Pantothenate Kinase-Associated Neurodegeneration: a Pilot Study
    RESEARCH ARTICLE Clinical Rating Scale for Pantothenate Kinase-Associated Neurodegeneration: A Pilot Study Alejandra Darling, MD,1 Cristina Tello, PhD,2 Marı´a Josep Martı´, MD, PhD,3 Cristina Garrido, MD,4 Sergio Aguilera-Albesa, MD, PhD,5 Miguel Tomas Vila, MD,6 Itziar Gaston, MD,7 Marcos Madruga, MD,8 Luis Gonzalez Gutierrez, MD,9 Julio Ramos Lizana, MD,10 Montserrat Pujol, MD,11 Tania Gavilan Iglesias, MD,12 Kylee Tustin,13 Jean Pierre Lin, MD, PhD,13 Giovanna Zorzi, MD, PhD,14 Nardo Nardocci, MD, PhD,14 Loreto Martorell, PhD,15 Gustavo Lorenzo Sanz, MD,16 Fuencisla Gutierrez, MD,17 Pedro J. Garcı´a, MD,18 Lidia Vela, MD,19 Carlos Hernandez Lahoz, MD,20 Juan Darı´o Ortigoza Escobar, MD,1 Laura Martı´ Sanchez, 1 Fradique Moreira, MD ,21 Miguel Coelho, MD,22 Leonor Correia Guedes,23 Ana Castro Caldas, MD,24 Joaquim Ferreira, MD,22,23 Paula Pires, MD,24 Cristina Costa, MD,25 Paulo Rego, MD,26 Marina Magalhaes,~ MD,27 Marı´a Stamelou, MD,28,29 Daniel Cuadras Palleja, MD,30 Carmen Rodrı´guez-Blazquez, PhD,31 Pablo Martı´nez-Martı´n, MD, PhD,31 Vincenzo Lupo, PhD,2 Leonidas Stefanis, MD,28 Roser Pons, MD,32 Carmen Espinos, PhD,2 Teresa Temudo, MD, PhD,4 and Belen Perez Duenas,~ MD, PhD1,33* 1Unit of Pediatric Movement Disorders, Hospital Sant Joan de Deu, Barcelona, Spain 2Unit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigacion Prı´ncipe Felipe, Valencia, Spain 3Neurology Department, Hospital Clı´nic de Barcelona, Institut d’Investigacions Biomediques IDIBAPS.
    [Show full text]
  • Management of Postpolio Syndrome
    Review Management of postpolio syndrome Henrik Gonzalez, Tomas Olsson, Kristian Borg Lancet Neurol 2010; 9: 634–42 Postpolio syndrome is characterised by the exacerbation of existing or new health problems, most often muscle weakness See Refl ection and Reaction and fatigability, general fatigue, and pain, after a period of stability subsequent to acute polio infection. Diagnosis is page 561 based on the presence of a lower motor neuron disorder that is supported by neurophysiological fi ndings, with exclusion Division of Rehabilitation of other disorders as causes of the new symptoms. The muscle-related eff ects of postpolio syndrome are possibly Medicine, Department of associated with an ongoing process of denervation and reinnervation, reaching a point at which denervation is no Clinical Sciences, Danderyd Hospital (H Gonzalez MD, longer compensated for by reinnervation. The cause of this denervation is unknown, but an infl ammatory process is K Borg MD) and Department of possible. Rehabilitation in patients with postpolio syndrome should take a multiprofessional and multidisciplinary Clinical Neurosciences, Centre approach, with an emphasis on physiotherapy, including enhanced or individually modifi ed physical activity, and muscle for Molecular Medicine training. Patients with postpolio syndrome should be advised to avoid both inactivity and overuse of weak muscles. (T Olsson MD), Karolinska Institute, Stockholm, Sweden Evaluation of the need for orthoses and assistive devices is often required. Correspondence to: Henrik Gonzalez, Division of Introduction summary of the pathophysiology and clinical Rehabilitation Medicine, 12–20 million people worldwide have sequelae of characteristics of postpolio syndrome, outline diagnostic Department of Clinical Sciences, poliomyelitis, according to Post-Polio Health and treatment options, and suggest future research Karolinska Institute, Danderyd Hospital, S-182 88 Stockholm, International.
    [Show full text]
  • The Migraine-Epilepsy Syndrome
    medigraphic Artemisaen línea Arch Neurocien (Mex) Vol 11, No. 4: 282-287, 2006 The Migraine- Epilepsy Syndrome Arch Neurocien (Mex) Vol. 11, No. 4: 282-287, 2006 Artículo de revisión ©INNN, 2006 de caso The migraine-epilepsy syndrome Enrique Otero Siliceo†, Fernando Zermeño EL SINDROME MIGRAÑA-EPILEPSIA represent a neural exitation. Since that the glutamate has in important rol in both patologys depending of the part of the brain more affected the symptoms might RESUMEN vary from visual to abdominal phemomena. La migraña y la epilepsia tienen varios puntos en común Key words: migraine epilepsy, EEG abnormalities, sintomática clínica y genéticamente lo que ha sido glutamate, diagnosis. postulado por más de cien años. El fenómeno referido como migraña-epilepsia sugiere que exista una he first steps of a practical, approach by patofisiología común. El síndrome de migraña o physicians in recognizing and treating neuro- epilepsia tiene fenómenos comunes de dolor adominal T logic diseases are to recognithat there are jaqueca anormalidades del EE y respuesta a droga various overlaps between migraine and epilepsy. antiepilépticas. En ocasiones el paciente puede tener Epileptic seizures and classic migraine episodes may un ataque migrañoso o una convulsión o en otras occur in the same patient. Migraine and epilepsy share ambas. La comorbilidad puede explicarse por estados several genetic, clinical, evolutive and neurophysio- de hiperrexcitabilidad neural. Alteraciones electroen- logic features. A relationship between epilepsy and cefalográficas son comunes en estos estados. En migraine has been postulated for over a hundred years apariencia el glutamato tiene un papel importante tanto and the syndrome of Migraine-Epilepsy illustrates this en la migraña como en la epilepsia.
    [Show full text]
  • Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000275 ISSN: 2329-6895
    olog eur ica N l D f i o s l o a r n d r e u r s o J Derakhshan, J Neurol Disord 2016, 4:4 Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000275 ISSN: 2329-6895 Research Article Open Access Successful Opioid Monotherapy in Migralepsy: A Case Series Iraj Derakhshan* Department of Neurology, Case Western Reserve and Cincinnati Universities, Ohio, USA *Corresponding author: Iraj Derakhshan, Associate Professor, Department of Neurology, Case Western Reserve and Cincinnati Universities, Ohio, 205 Cyrus Drive, Charleston West Virginia, 25314, USA, Tel: 304 345 5174; E-mail: [email protected] Rec date: June 10, 2016; Acc date: July 06, 2016; Pub date: July 10, 2016 Copyright: © 2016 Derakhshan I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: There is a consensus that migraine and epilepsy are comorbid conditions. The novel concept explored and developed in this case series is that of the primacy of headaches in generating seizures in those patients suffering from migraine-triggered epilepsy (i.e., migralepsy). As demonstrated in the five cases descried here, much like the effect of ketogenic-diet on migraine-triggered epilepsy, once the migraine headaches were completely suppressed after adopting daily scheduled opioid therapy the seizures stopped from occurring, but they returned with the recurrence of the migraines once the patients had stopped their daily opiate regimen for any reason. Clinical implications: The above pharmacological scenario is reminiscent of a similar but naturalistic course of events as described in reports concerning the salutary effects of ketogenic diet, or restoration of sleep, in cases of migraine-triggered epilepsy.
    [Show full text]
  • Migraine Mimics
    ISSN 0017-8748 Headache doi: 10.1111/head.12518 © 2015 American Headache Society Published by Wiley Periodicals, Inc. Expert Opinion Migraine Mimics Randolph W. Evans, MD The symptoms of migraine are non-specific and can be present in many other primary and secondary headache disorders, which are reviewed. Even experienced headache specialists may be challenged at times when diagnosing what appears to be first or worst, new type, migraine status, and chronic migraine. Key words: migraine, migraine mimic, symptomatic migraine, hemicrania continua (Headache 2015;55:313-322) The symptoms of migraine are non-specific and She had seen 2 headache specialists previously. can be present in many other primary and secondary She had been tried on sumatriptan p.o. and subcuta- headache disorders.1,2 Even experienced headache neously, diclofenac powder, ketorolac oral and intra- specialists may be challenged at times when diagnos- muscular, dihydroergotamine nasal spray, and had an ing what appears to be first or worst, new type, occipital nerve block without benefit. Gabapentin migraine status, and chronic migraine. Another diag- and pregabalin did not help. She was placed on indo- nosis may be responsible when physicians use the term methacin 75 mg sustained release once a day for 8 “atypical migraine.” days without benefit. Prednisone 60 mg daily for 10 days did not help.An intravenous dihydroergotamine CASE HISTORIES regimen for 5 days did not help. Case 1.—This 48-year-old woman was seen for a A magnetic resonance imaging (MRI) and mag- third opinion with a 20-year history of only menstrual netic resonance angiogram (MRA) of the brain and headaches always preceded by a visual aura followed cervical spine and magnetic resonance venogram by a generalized throbbing with an intensity of 5–6/10 (MRV) of the brain were negative.
    [Show full text]
  • Persistent Visual Noise (Visual Snow Syndrome)
    Journal of Ophthalmology & Visual Neurosciences Case Report Persistent Visual Noise (Visual Snow Syndrome) This article was published in the following Scient Open Access Journal: Journal of Ophthalmology & Visual Neurosciences Received September 22, 2017; Accepted September 27, 2017; Published October 04, 2017 Al Mamoori Fawwaz* and Moath al Horani Department of Medical Retina and Keywords: Visual Snow, Excitability of the cerebral cortex (Hyper metabolism), Neurophthalmology, Eye Specialty Hospital, Amman, Continuous flickering dots, Migraines Aura Jordan Introduction Visual Snow Syndrom is a disorder of altered visual perception in which the patients eyes similar to the pixels of an old television. see continuous flickering tiny black and white dots across the entire visual field of both The visual noise occurs 24/7 with eyes open and closed. Visual Snow is a part of unique syndrome that is different from visual aura in migrane.it was diagnosed for the first time in 1995 by Dr. Schankin MD Fellow in the department of neurology, University of California, San Francisco. Patients may describe other visual symptoms like floaters, afterimages, flashes in addition to headache, tinnitus, anxiety or depression. Most of the affected patients are young and otherwise healthy, often in the second to the fourth decade of life. The cause of syndrome is unclear [1]. The supposed mechanism is excessive activity or excitability of the cerebral cortex neurons that including the thalamic reticular nucleus, Parietal lobe and pre frontal lobe. ThereMethod is no cure for this syndrome until now [2-4]. her 26vision. y old female, has attended our clinic, complaining from persistent noise in her vision (day and night 24/7) that described as black & white dots in the entire field of sym Also she reported difficulties in night vision in addition to other non-ophthalmic ptoms like headache, tinnitus, loss of appetite and pain in tempero-mandibular joint (Figures 1 and 2).
    [Show full text]
  • Visual Snow Syndrome a Clinical and Phenotypical Description of 1,100 Cases
    ARTICLE OPEN ACCESS Visual snow syndrome A clinical and phenotypical description of 1,100 cases Francesca Puledda, MD, Christoph Schankin, MD, and Peter J. Goadsby, MD, PhD Correspondence Dr. Puledda Neurology® 2020;94:e564-e574. doi:10.1212/WNL.0000000000008909 [email protected] Abstract RELATED ARTICLE Objective Editorial To validate the current criteria of visual snow and to describe its common phenotype using Visual snow: Are we a substantial clinical database. beginning to see the light? Page 241 Methods We performed a web-based survey of patients with self-assessed visual snow (n = 1,104), with MORE ONLINE either the complete visual snow syndrome (n = 1,061) or visual snow without the syndrome Podcast (n = 43). We also describe a population of patients (n = 70) with possible hallucinogen Dr. Teshamae Monteith persisting perception disorder who presented clinically with visual snow syndrome. talks with Dr. Francesca Puledda about her paper Results providing a clinical and The visual snow population had an average age of 29 years and had no sex prevalence. The phenotypical description ≈ disorder usually started in early life, and 40% of patients had symptoms for as long as they of visual snow syndrome. could remember. The most commonly experienced static was black and white. Floaters, NPub.org/fxcblh afterimages, and photophobia were the most reported additional visual symptoms. A latent class analysis showed that visual snow does not present with specific clinical endophenotypes. Severity can be classified by the amount of visual symptoms experienced. Migraine and tinnitus CME Course NPub.org/cmelist had a very high prevalence and were independently associated with a more severe presentation of the syndrome.
    [Show full text]
  • Decreased Risk of Dementia in Migraine Patients with Traditional Chinese Medicine Use: a Population-Based Cohort Study
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 45), pp: 79680-79692 Clinical Research Paper Decreased risk of dementia in migraine patients with traditional Chinese medicine use: a population-based cohort study Chun-Ting Liu1,*, Bei-Yu Wu1,*, Yu-Chiang Hung1,2,*, Lin-Yi Wang3, Yan-Yuh Lee3, Tsu-Kung Lin4, Pao-Yen Lin5, Wu-Fu Chen6, Jen-Huai Chiang7,8, Sheng-Feng Hsu9,10 and Wen-Long Hu1,11,12,* 1Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Kaohsiung, Taiwan 2School of Chinese Medicine for Post Baccalaureate, I-Shou University, Kaohsiung, Taiwan 3Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan 4Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan 5Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan 6Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan 7Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan 8College of Medicine, China Medical University, Taichung, Taiwan 9Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan 10Department of Chinese Medicine, China Medical University Hospital, Taipei Branch, Taipei, Taiwan 11Kaohsiung Medical University College of Medicine, Kaohsiung, Taiwan 12Fooyin University College of Nursing, Kaohsiung, Taiwan *These authors contributed equally to this work Correspondence to: Wen-Long Hu, email: [email protected] Keywords: dementia, migraine, pharmaco-epidemiology, national health insurance research database, Chinese herbal product Received: February 27, 2017 Accepted: June 28, 2017 Published: July 08, 2017 Copyright: Liu et al.
    [Show full text]
  • Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis
    1340 • The Journal of Neuroscience, February 11, 2004 • 24(6):1340–1349 Neurobiology of Disease Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis Minh Dang Nguyen,1 Thierry D’Aigle,2 Genevie`ve Gowing,1,2 Jean-Pierre Julien,1,2 and Serge Rivest2 1McGill University Health Center, Centre for Research in Neurosciences, McGill University, The Montreal General Hospital Research Institute, Montre´al, Que´bec H3G 1A4, Canada, and 2Laboratory of Molecular Endocrinology, Laval University Medical Center Research Center and Department of Anatomy and Physiology, Laval University, Sainte-Foy, Que´bec G1V 4G2, Canada Innate immunity is a specific and organized immunological program engaged by peripheral organs and the CNS to maintain homeostasis after stress and injury. In neurodegenerative disorders, its putative deregulation, featured by inflammation and activation of glial cells resulting from inherited mutations or viral/bacterial infections, likely contributes to neuronal death. However, it remains unclear to what extent environmental factors and innate immunity cooperate to modulate the interactions between the neuronal and non-neuronal elements in the perturbed CNS. In the present study, we addressed the effects of acute and chronic administration of lipopolysaccharide (LPS), a Gram-negative bacterial wall component, in a genetic model of neurodegeneration. Transgenic mice expressing a mutant form of the superoxide dismutase 1 (SOD1 G37R) linked to familial amyotrophic lateral sclerosis were challenged intraperitoneally with a single nontoxic or repeated injections of LPS (1 mg/kg). At different ages, SOD1 G37R mice responded normally to acute endotoxemia. Remark- ably, only a chronic challenge with LPS in presymptomatic 6-month-old SOD1 G37R mice exacerbated disease progression by 3 weeks and motor axon degeneration.
    [Show full text]
  • Treatment for Disease Modification in Chronic Neurodegeneration
    cells Review Perspective: Treatment for Disease Modification in Chronic Neurodegeneration Thomas Müller 1,* , Bernhard Klaus Mueller 1 and Peter Riederer 2,3 1 Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Gartenstr. 1, 13088 Berlin, Germany; [email protected] 2 Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Margarete-Höppel-Platz 1, 97080 Würzburg, Germany; [email protected] 3 Department of Psychiatry, Southern Denmark University Odense, J.B. Winslows Vey 18, 5000 Odense, Denmark * Correspondence: [email protected] Abstract: Symptomatic treatments are available for Parkinson’s disease and Alzheimer’s disease. An unmet need is cure or disease modification. This review discusses possible reasons for negative clinical study outcomes on disease modification following promising positive findings from experi- mental research. It scrutinizes current research paradigms for disease modification with antibodies against pathological protein enrichment, such as α-synuclein, amyloid or tau, based on post mortem findings. Instead a more uniform regenerative and reparative therapeutic approach for chronic neurodegenerative disease entities is proposed with stimulation of an endogenously existing repair system, which acts independent of specific disease mechanisms. The repulsive guidance molecule A pathway is involved in the regulation of peripheral and central neuronal restoration. Therapeutic antagonism of repulsive guidance molecule A reverses neurodegeneration according to experimental Citation: Müller, T.; Mueller, B.K.; outcomes in numerous disease models in rodents and monkeys. Antibodies against repulsive guid- Riederer, P. Perspective: Treatment for ance molecule A exist. First clinical studies in neurological conditions with an acute onset are under Disease Modification in Chronic Neurodegeneration. Cells 2021, 10, way.
    [Show full text]
  • Gut–Brain Axis and Neurodegeneration: State-Of-The-Art of Meta-Omics Sciences for Microbiota Characterization
    International Journal of Molecular Sciences Review Gut–Brain Axis and Neurodegeneration: State-of-the-Art of Meta-Omics Sciences for Microbiota Characterization Bruno Tilocca 1 , Luisa Pieroni 2 , Alessio Soggiu 3,4 , Domenico Britti 1 , Luigi Bonizzi 4, 1, , 5,6, Paola Roncada * y and Viviana Greco * 1 Department of Health Sciences, University “Magna Græcia” of Catanzaro, viale Europa, 88100 Catanzaro, Italy; [email protected] (B.T.); [email protected] (D.B.) 2 Proteomics and Metabonomics Unit, Fondazione Santa Lucia-IRCCS, via del Fosso di Fiorano, 64-00143 Rome, Italy; [email protected] 3 Department of Biomedical, Surgical and Dental Sciences- One Health Unit, University of Milano, via Celoria 10, 20133 Milano, Italy; [email protected] 4 Department of Veterinary Medicine, University of Milano, Via dell’Università, 6- 26900 Lodi, Italy; [email protected] 5 Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy 6 Fondazione Policlinico Universitario Agostino Gemelli, Largo A. Gemelli, 8-00168 Rome, Italy * Correspondence: [email protected] (P.R.); [email protected] (V.G.) Which represents the co-corresponding author. y Received: 14 May 2020; Accepted: 4 June 2020; Published: 5 June 2020 Abstract: Recent advances in the field of meta-omics sciences and related bioinformatics tools have allowed a comprehensive investigation of human-associated microbiota and its contribution to achieving and maintaining the homeostatic balance. Bioactive compounds from the microbial community harboring the human gut are involved in a finely tuned network of interconnections with the host, orchestrating a wide variety of physiological processes.
    [Show full text]